What Does the Complete Evidence Say About PPIs and Bone Health?
This is an umbrella review, a synthesis of existing systematic reviews and meta-analyses rather than a new trial. It reports that long-term proton pump inhibitor use may be associated with adverse bone health outcomes: increased fracture risk, changes in bone mineral density, hypomagnesemia, and dental implant failure. The increased risk of fractures, notably hip, spine, and wrist fractures, was statistically significant in PPI users. The certainty of most of that evidence, graded by GRADE criteria, ranged from very low to low.
Dr. Kumar’s Take
I read this as a signal worth paying attention to, not a settled case. The fracture association reaches statistical significance across the pooled literature, and that is enough for me to think about bone health when I am deciding whether a patient stays on acid suppression indefinitely. But the authors themselves grade most of this evidence as very low to low certainty, and they say the clinical relevance of the bone mineral density changes remains uncertain. That is an honest reading of a messy literature. My practical response is not to stop prescribing PPIs when they are indicated, it is to keep asking whether the indication still holds. The authors call for robust, high-quality research to clarify these associations, and I agree that is what the question needs.
What the Research Shows
The authors searched PubMed, Web of Science, Embase, and the Cochrane database through September 16, 2023, looking for systematic reviews and meta-analyses of randomized controlled trials and observational studies that evaluated the relationship between PPIs and bone metabolism outcomes. Data extraction, quality appraisal, and synthesis followed Joanna Briggs Institute and PRISMA guidelines, with evidence strength graded using GRADE criteria and statistical analysis performed in R version 4.3.
Across that body of work, PPI use was associated with a statistically significant increase in fracture risk, with hip, spine, and wrist fractures specifically noted. PPI use was also associated with changes in bone mineral density across various bones, though the clinical relevance of those changes remains uncertain. The review additionally identified PPI-induced hypomagnesemia, which can influence bone health, and an increased risk of dental implant failure in PPI users.
Study Snapshot
Out of 299 records screened, 27 studies met the inclusion criteria. All were systematic reviews or meta-analyses of randomized controlled trials and observational studies examining PPIs and bone metabolism outcomes. Outcomes covered fracture risk including hip, spine, and wrist fractures, bone mineral density, magnesium status, and dental implant failure.
Results in Real Numbers
- Records screened: 299
- Studies included: 27 systematic reviews and meta-analyses
- Search cutoff: September 16, 2023
- Fracture risk: statistically significant increase in PPI users, notably hip, spine, and wrist fractures
- Bone mineral density: changes across various bones, clinical relevance uncertain
- Other findings: PPI-induced hypomagnesemia, and increased risk of dental implant failure
- Certainty of evidence: very low to low for most findings by GRADE criteria
Safety, Limits, and Caveats
The dominant limitation is the certainty of the evidence itself. The authors graded most findings as very low to low by GRADE, which means the pooled estimates could shift substantially with better data. The bone mineral density signal is the clearest example: the changes are there, but whether they matter clinically is not established.
An umbrella review also inherits the limitations of the reviews it summarizes. The underlying literature includes observational studies, which can show association but not causation. The authors conclude that robust, high-quality research is needed to clarify these associations, and until that exists, these findings should be read as potential concerns for long-term PPI users rather than established harms.
Practical Takeaways
- Treat long-term PPI use, not short-term use, as the setting where these concerns apply. The review’s conclusion is framed around long-term therapy.
- Reassess periodically whether the PPI indication still holds, since the risk signal attaches to continued use.
- Be aware that fracture risk, bone mineral density, magnesium status, and dental implant outcomes were all flagged in this synthesis.
- If a patient on chronic PPI therapy is being planned for a dental implant, the increased failure risk identified here is worth raising with the treating dentist.
- Hold these findings loosely. The authors themselves rate most of the evidence as very low to low certainty, so they should inform a conversation rather than dictate a decision.
Related Studies and Research
- Proton Pump Inhibitors and Risk of Fractures: Meta-Analysis of 11 International Studies
- Proton Pump Inhibitors and Osteoporosis: Is Collagen a Direct Target?
- Use of Proton Pump Inhibitors and Risk of Iron Deficiency: Population-Based Study
- Pharmacology of Proton Pump Inhibitors
- Episode 25: The Great GERD Mistake - How Medicine Made Heartburn Worse and How to Fix It
FAQs
How strong is the evidence linking PPIs to bone problems?
The fracture association was statistically significant, but the authors graded the certainty of most of the evidence in this review as very low to low using GRADE criteria. That is a real signal in a literature that is not yet strong enough to settle the question.
Which fractures were involved?
Hip, spine, and wrist fractures were specifically noted among PPI users.
Do PPIs change bone density?
PPI use was associated with changes in bone mineral density across various bones. The authors state that the clinical relevance of these changes remains uncertain.
Is there anything here beyond fractures and bone density?
Yes. The review identified PPI-induced hypomagnesemia, which can influence bone health, and an increased risk of dental implant failure in PPI users.
Should I stop my PPI because of this?
No, not on the basis of this review. It describes potential concerns associated with long-term use and calls for higher-quality research to clarify them. If you are on a PPI indefinitely, the reasonable step is to ask your physician whether the indication still applies, not to stop on your own.
Bottom Line
This umbrella review of 27 systematic reviews and meta-analyses found that long-term PPI use may be associated with adverse bone health outcomes: a statistically significant increase in fracture risk, changes in bone mineral density of uncertain clinical relevance, hypomagnesemia, and dental implant failure. The certainty of most of that evidence was very low to low, so the findings identify potential concerns for long-term users and a need for better research, not a settled verdict.
